Arvinas to Present at the 3rd Annual Targeted Protein Degradation Summit
October 06, 2020 17:17 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the Citi 15th Annual BioPharma Virtual Conference
September 04, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 16, 2020 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
June 25, 2019 07:00 ET
|
Arvinas Inc.
- Initiation of Phase 1 Trial expected in the third quarter of 2019 - ARV-471 will be Arvinas’ second targeted PROTAC® protein degrader to enter the clinic NEW HAVEN, Conn., June 25, 2019 ...
Arvinas Reports First Quarter Financial Results and Provides Corporate Update
May 08, 2019 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today reported...
Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
December 07, 2018 19:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented positive...